Serum exosomal long noncoding RNA nuclear-enriched abundant transcript 1 predicts 90-day mortality in acute-on-chronic hepatitis B liver failure. (3rd July 2021)

• Record Type: Journal Article
• Authors: Gao, Shuai; Fan, Yu-Chen; Han, Li-Yan; Wang, Kai
• Is Part Of: Expert review of clinical immunology. Volume 17:Number 7(2021)
• Page Start: 789
• Page End: 797
• Publication Date: 2021-07-03
• Subjects: Biomarker -- exosome -- LncRNA -- NEAT1 -- prognosis; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1080/1744666X.2021.1933442
• Languages: English
• ISSNs: 1744-666X

Abstract

ABSTRACT: Objectives : Acute-on-chronic hepatitis B liver failure (ACHBLF) is characterized by high short-term mortality, calling for accurate prognostic biomarkers. This study aims to evaluate the predictive value of serum exosomal long noncoding RNA nuclear-enriched abundant transcript 1 (lncRNA NEAT1) for 90-day mortality of ACHBLF. Methods : This prospective study consisted of 113 ACHBLF patients from June 2013 to June 2017 as a training cohort and 72 ACHBLF patients from July 2017 to June 2020 as a validating cohort. LncRNA NEAT1 was detected using quantitative real-time polymerase chain reaction from serum exosomes. Results : LncRNA NEAT1 levels were higher in non-survivors than survivors ( P < 0.01). In the training cohort, lncRNA NEAT1 (HR 1.049, 95%CI 1.023–1.075, P < 0.001) was an independent predictor for 90-day mortality of ACHBLF. Meanwhile, lncRNA NEAT1 showed significantly higher area under the curve of receiver operating characteristic (AUC) than MELD score in the training and validation cohort ( P < 0.05, respectively). However, no significant difference was found in AUC between lncRNA NEAT1 and NEAT1 plus MELD score ( P > 0.05). ACHBLF patients with lncRNA NEAT1 levels above 1.92 showed poorer survival condition than those below ( P < 0.01). Conclusions : The serum exosomal lncRNA NEAT1 might be a better prognostic biomarker than MELD score for 90-day mortality of ACHBLF.